Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Depreciation & Amortization (CF) (2016 - 2025)

Standard Biotools (LAB) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 51.67% to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.1 million, a 6.01% increase, with the full-year FY2024 number at $12.5 million, up 214.45% from a year prior.
  • Depreciation & Amortization (CF) was $1.5 million for Q3 2025 at Standard Biotools, down from $3.2 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.0 million in Q2 2021 to a low of -$3.2 million in Q3 2021.
  • A 5-year average of $1.7 million and a median of $1.1 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Biggest YoY gain for Depreciation & Amortization (CF) was 444.48% in 2021; the steepest drop was 431.38% in 2021.
  • Standard Biotools' Depreciation & Amortization (CF) stood at $909000.0 in 2021, then decreased by 9.9% to $819000.0 in 2022, then soared by 35.04% to $1.1 million in 2023, then soared by 183.91% to $3.1 million in 2024, then tumbled by 51.56% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Depreciation & Amortization (CF) are $1.5 million (Q3 2025), $3.2 million (Q2 2025), and $3.3 million (Q1 2025).